Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neumora Therapeutics (NMRA) Change in Cash (2022 - 2026)

Neumora Therapeutics' quarterly Change in Cash came in at -$35.5 million in Q1 2026, down 131.93% year-on-year from $111.0 million in Q1 2025, and down 166.33% quarter-over-quarter from $53.5 million in Q4 2025.

Neumora Therapeutics has reported Change in Cash for 5 years, with the latest figure at -$35.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash fell 131.93% year-over-year to -$35.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.0 million (up 133.89% YoY), and the FY2025 full-year result was $39.2 million, up 116.89% from the prior year.
  • Change in Cash for Q1 2026 stood at -$35.5 million, down from $53.5 million in the prior quarter.
  • The five-year high for Change in Cash was $208.1 million in Q3 2023, with the low at -$191.1 million in Q1 2024.
  • Average Change in Cash over 5 years is -$7.6 million, with a median of -$13.4 million recorded in 2022.
  • Year-over-year, Change in Cash sank 534.44% in 2024 and soared 140.02% in 2025.
  • Tracing NMRA's Change in Cash over 5 years: stood at -$11.6 million in 2022, then slumped by 230.76% to -$38.2 million in 2023, then sank by 249.23% to -$133.6 million in 2024, then soared by 140.02% to $53.5 million in 2025, then plunged by 166.33% to -$35.5 million in 2026.
  • The last three Change in Cash figures came in at -$35.5 million (Q1 2026), $53.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 Neumora Therapeutics 328.27 Mn 328.27 Mn - -35.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -35.46 Mn
Dec 31, 2025 53.46 Mn
Sep 30, 2025 4.55 Mn
Jun 30, 2025 -3.55 Mn
Mar 31, 2025 -15.29 Mn
Dec 31, 2024 -133.57 Mn
Sep 30, 2024 125.04 Mn
Jun 30, 2024 -32.25 Mn
Mar 31, 2024 -191.11 Mn
Dec 31, 2023 -38.25 Mn
Sep 30, 2023 208.07 Mn
Jun 30, 2023 -6.65 Mn
Mar 31, 2023 -30.12 Mn
Dec 31, 2022 -11.56 Mn